EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Vonoprazan is Efficacious for Treatment of Heartburn in Non-erosive Reflux Disease: A Randomized Trial

Loren Laine, Stuart Spechler, Rena Yadlapati, Felice Schnoll-Sussman, Neila Smith, Eckhard Leifke, Tom Harris, Barbara Hunt, Ronnie Fass, Philip Katz

Clinical Gastroenterology and Hepatology · 2024-11 · 22 (11) · 2211-2220.e10

DOI: 10.1016/j.cgh.2024.05.004 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2024-11. Verfasst von Loren Laine und 9 weiteren Autor:innen. Beteiligte Einrichtung: Yale School of Medicine, New Haven, Connecticut; VA Connecticut Healthcare System, West Haven, Connecticut. Electronic address: loren.laine@yale.edu. Hauptthemen laut MEDLINE: Pyrroles, Sulfonamides, Heartburn, Gastroesophageal Reflux. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Potassium-competitive acid blockers have documented efficacy for erosive esophagitis. We performed a randomized trial in United States subjects diagnosed with non-erosive reflux disease of vonoprazan vs placebo for 4 weeks, followed by a 20-week active-treatment extension. METHODS: Adult subjects with heartburn ≥4 days/week during screening without erosive esophagitis on endoscopy were randomized to placebo, vonoprazan 10 mg, or vonoprazan 20 mg. After 4 weeks, subjects on placebo were re-randomized to vonoprazan 10 mg or 20 mg, and those already on vonoprazan continued at the same dose for 20 weeks. Electronic diaries were completed twice daily. The primary endpoint was percentage of days without daytime or nighttime heartburn (24-hour heartburn-free days). RESULTS: Among 772 randomized subjects, the percentage of 24-hour heartburn-free days was 27.7% for placebo vs 44.8% for vonoprazan 10 mg (least squares mean difference, 17.1%; P < .0001) and 44.4% for vonoprazan 20 mg (least squares mean difference, 16.7%; P < .0001). Differences in percentage of subjects with a 24-hour heartburn-free day for vonoprazan 10 mg vs placebo and vonoprazan 20 mg vs placebo were 8.3% and 11.6% on day 1 and 18.1% and 23.2% on day 2. The mean/median percentages of 24-hour heartburn-free days over the extension period were similar across the 4 study arms: 61%-63%/76%-79%. CONCLUSIONS: Vonoprazan reduced heartburn symptoms in subjects diagnosed with non-erosive reflux disease, with the benefit appearing to begin as early as the first day of therapy. Treatment effect persisted after the initial 4-week placebo-controlled period throughout the 20-week extension period. The 2 vonoprazan doses (10 mg and 20 mg) were similar in efficacy. (ClinicalTrials.gov: NCT05195528).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrrolesSulfonamidesHeartburnGastroesophageal RefluxHumansMaleFemaleMiddle AgedTreatment OutcomeAdultAgedPlacebosUnited StatesYoung AdultDouble-Blind MethodNon-Erosive Reflux Disease

Stichwörter der Autor:innen

Gastroesophageal RefluxHeartburnPotassium-competitive Acid Blocker

Substanzen

1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanaminePyrrolesSulfonamidesPlacebos

Autor:innen und Institutionen

  • Yale School of Medicine, New Haven, Connecticut; VA Connecticut Healthcare System, West Haven, Connecticut. Electronic address: loren.laine@yale.edu.
  • Baylor University Medical Center, Dallas, Texas; Baylor Scott & White Research Institute, Dallas, Texas.
  • University of California San Diego, La Jolla, California.
  • Weill Cornell Medicine, New York, New York.
  • Phathom Pharmaceuticals, Buffalo Grove, Illinois.
  • MetroHealth Medical System, Case Western Reserve University, Cleveland, Ohio.

Zitieren

APA

Laine, L., Spechler, S., Yadlapati, R., Schnoll-Sussman, F., Smith, N., Leifke, E., Harris, T., Hunt, B., Fass, R., & Katz, P. (2024). Vonoprazan is Efficacious for Treatment of Heartburn in Non-erosive Reflux Disease: A Randomized Trial. Clinical Gastroenterology and Hepatology, 22(11), 2211-2220.e10. https://doi.org/10.1016/j.cgh.2024.05.004

Vancouver

Laine L, Spechler S, Yadlapati R, Schnoll-Sussman F, Smith N, Leifke E, et al. Vonoprazan is Efficacious for Treatment of Heartburn in Non-erosive Reflux Disease: A Randomized Trial. Clinical Gastroenterology and Hepatology. 2024;22(11):2211-2220.e10. doi:10.1016/j.cgh.2024.05.004

BibTeX
@article{Laine2024,
  author = {Laine, Loren and Spechler, Stuart and Yadlapati, Rena and Schnoll-Sussman, Felice and Smith, Neila and Leifke, Eckhard and Harris, Tom and Hunt, Barbara and Fass, Ronnie and Katz, Philip},
  title = {Vonoprazan is Efficacious for Treatment of Heartburn in Non-erosive Reflux Disease: A Randomized Trial},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2024},
  volume = {22},
  number = {11},
  pages = {2211--2220.e10},
  doi = {10.1016/j.cgh.2024.05.004}
}
Kostenlos starten →